Sequoia Financial Advisors LLC Reduces Position in Pfizer Inc. $PFE

Sequoia Financial Advisors LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 6.2% in the second quarter, Holdings Channel reports. The fund owned 332,178 shares of the biopharmaceutical company’s stock after selling 21,947 shares during the period. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $7,999,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the fourth quarter worth about $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer during the second quarter worth $26,000. Field & Main Bank purchased a new position in Pfizer during the 2nd quarter valued at about $27,000. HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $27.69 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $157.82 billion, a P/E ratio of 36.43, a P/E/G ratio of 1.86 and a beta of 0.34. The business has a fifty day simple moving average of $26.35 and a 200-day simple moving average of $26.37. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.21.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. Finally, Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.39.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.